Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 654 of 5804
-
Could less chemo be enough for some kids with rhabdomyosarcoma?
Disease control Recruiting nowRhabdomyosarcoma is a type of cancer that occurs in the soft tissues in the body. This phase III trial aims to maintain excellent outcomes in patients with very low risk rhabdomyosarcoma (VLR-RMS) while decreasing the burden of therapy using treatment with 24 weeks of vincristine…
Phase: PHASE3 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New trial aims to give every blood cancer patient a donor
Disease control Recruiting nowThis study is a single center, prospective, single arm exploratory clinical trial that includes patients with hematological malignancies who are indicated for allogeneic hematopoietic stem cell transplantation (allo HSCT) but lack suitable donors. This project plans to use highly…
Phase: PHASE1 • Sponsor: He Huang • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New drug aims to tame Sjogren's syndrome in major trial
Disease control OngoingA randomized, double-blind, placebo controlled, 3-arm multicenter phase 3 study to assess the efficacy and safety of ianalumab in patients with active Sjogren's syndrome (NEPTUNUS-2)
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New COVID pill shows promise in large trial
Disease control CompletedThe main aim of this study is to evaluate the efficacy of S-217622 versus placebo among outpatient adults with mild and moderate COVID-19 starting intervention within 3 days of symptom onset.
Phase: PHASE3 • Sponsor: Shionogi • Aim: Disease control
Last updated Jun 26, 2026 18:01 UTC
-
New hope for liver patients: drug may delay brain fog and hospital stays
Disease control OngoingStudy RNLC3132 is a Phase 3, randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of rifaximin SSD-40mg IR for the delay of the first episode of overt hepatic encephalopathy (OHE) decompensation in liver cirrhosis, defined by the prese…
Phase: PHASE3 • Sponsor: Bausch Health Americas, Inc. • Aim: Disease control
Last updated Jun 26, 2026 16:50 UTC
-
New pill targets Hard-to-Treat cancer mutation
Disease control Recruiting nowThis is a first-in-human (FIH), multicenter, open-label, dose-escalation, and dose-expansion Phase 1/2 clinical trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of D3S-001 or combination therapy in subjects with advanced KRA…
Phase: PHASE1, PHASE2 • Sponsor: D3 Bio (Wuxi) Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New combo aims to slow advanced breast cancer
Disease control OngoingThis Phase III, randomized, open-label, multicenter study will evaluate the efficacy and safety of giredestrant plus everolimus compared with the physician's choice of endocrine therapy plus everolimus in participants with estrogen receptor (ER)-positive, human epidermal growth f…
Phase: PHASE3 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Green light and pink dye take on tough eye infections
Disease control CompletedRose Bengal Electromagnetic Activation with Green light for Infection Reduction (REAGIR ) is an international, randomized, doubled masked, clinical trial. The purpose of this study is to determine differences in 6-month visual acuity between medical antimicrobial treatments alone…
Phase: PHASE3 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New bispecific antibody shows promise for unresectable liver cancer
Disease control CompletedPhase II open label, multicenter study to evaluate the efficacy and safety of AK112 (PD-1/VEGF Bispecific) in patients with unresectable hepatocellular carcinoma (HCC).
Phase: PHASE2 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
New hope for lung cancer patients whose current drug stops working
Disease control OngoingClinical study to investigate the efficacy and safety of savolitinib in combination with osimertinib versus platinum-based doublet chemotherapy in participants with EGFR mutated, MET-overexpressed and/or amplified, locally advanced or metastatic NSCLC who have progressed on treat…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New hope for tough lymphomas: experimental drug STP938 enters human trials
Disease control Recruiting nowThe Phase 1 part of the study is a dose escalation of STP938 as monotherapy. The Phase 2 part of the study is cohort expansion of STP938 as a monotherapy in 5 different B and T cell lymphomas.
Phase: PHASE1, PHASE2 • Sponsor: Step Pharma, SAS • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Stomach bug treatment in teens could stop cancer before it starts
Disease control Recruiting nowGastric cancer remains a global health problem, and Chile has one of the highest GC mortality rates in the region. Helicobacter pylori (H. pylori) infection is ubiquitous in Chilean adults, and it constitutes the main cause of GC worldwide. A long-term process occurs from premali…
Phase: NA • Sponsor: Miguel O'Ryan Gallardo • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New antibody drug could open door to kidney transplants for Hard-to-Match patients
Disease control OngoingThe purpose of this study is to determine whether vonsetamig will safely decrease anti-HLA antibodies to allow for kidney transplantation. Vonsetamig is being studied for treatment of patients in need of kidney transplantation who are highly sensitized to HLA. The study is look…
Phase: PHASE1, PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New blood thinner cocktails aim to outsmart stroke in High-Risk patients
Disease control OngoingThe primary goal of the trial is to determine if the experimental arms (rivaroxaban or ticagrelor or both) are superior to the clopidogrel arm for lowering the 1-year rate of ischemic stroke, intracerebral hemorrhage, or vascular death.
Phase: PHASE3 • Sponsor: University of Florida • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Blood test may spare thousands of kids from unnecessary CT scans after head injury
Diagnosis CompletedMild traumatic brain injury (TBI), defined by a Glasgow Coma Scale (GCS) score of 13 to 15, is the cause of many consultations in paediatric emergency departments (1), even though it is a rare cause of acute complication: approximately 10% of children present with intracranial le…
Phase: NA • Sponsor: Nantes University Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 13:00 UTC
-
New hope for leukemia patients: drug targets hidden cancer cells after transplant
Disease control Recruiting nowAs part of postremission consolidative therapy, the decision to proceed with hematopoietic stem cell transplantation is a recommendable regimen in ALL therapy. However, The recurrence rate is high after transplantation. Minimal Residual Disease (MRD) is an important factor affect…
Phase: PHASE2 • Sponsor: Sheng-Li Xue, MD • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New drug duo aims to tame rare blood disorder
Disease control OngoingThis study is researching a clinical treatment combination with two experimental drugs called pozelimab and cemdisiran. The study is focused on people with paroxysmal nocturnal hemoglobinuria (PNH). The aim of the study is to see how safe and effective the pozelimab + cemdisiran …
Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Shorter PTSD therapy shows promise for veterans who drop out early
Symptom relief CompletedCognitive Processing Therapy (CPT) consists of discrete therapeutic components that are delivered across 12 sessions, but most Veterans never reach session 12, and those who drop out receive only 4 sessions on average. Veterans drop out because of time constraints, logistics, and…
Phase: NA • Sponsor: VA Office of Research and Development • Aim: Symptom relief
Last updated Jun 27, 2026 13:06 UTC
-
New stem cell infusion could boost transplant success in rare blood disorder
Disease control ENROLLING_BY_INVITATIONEfficacy and Safety of Sequential Infusion of Hypoxic 3D-Cultured Umbilical Cord Mesenchymal Stem Cells in Haploidentical Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia: A Multicenter, Randomized, Phase 1 Trial
Phase: PHASE1, PHASE2 • Sponsor: Chinese PLA General Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug cocktail targets Hard-to-Treat lung cancer mutation
Disease control OngoingThis is a prospective, single-arm, multicenter, phase II study to investigate the efficacy and safety of Ensartinib plus Bevacizumab in metastatic anaplastic lymphoma kinase (ALK)-rearranged Non-Small Cell Lung Cancer (NSCLC) with TP53 mutation.
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC